

CNS Drug Development

The future of neuropharmacology

Focus on stem cell and regenerative therapies in CNS drug discovery

15th - 16th December 2008, BSG Conference Centre, London, UK

BOOK NOW!

Key Speakers

Jackie Hunter, Senior Vice President, Science Environment Development, **GlaxoSmithKline**

Johan Luthman, Global Head Exploratory Medicine, PoC Management & Liaison, **Merck Serono**

Mark Tricklebank, Director, Senior Research Fellow- Psychiatric Disorders Drug Hunting Team, **Lilly UK**

Simon Lovestone, Director NIHR Biomedical Research Centre for Mental Health, Institute of Psychiatry, **King's College London**

Simone Braggio, Director, Neurosciences CEDD DMPK, **GlaxoSmithKline**

Keith Wesnes, Chief Executive, **Cognitive Drug Research**

Rémy Luthringer, Chief Executive Officer, **Forenap Pharma**

Claude Wischik, Executive Chairman, **TauRx Therapeutics**

Hinnerk Boriss, Chief Executive Officer, **Sovicell**

Ann Hayes, Owner, **The Ann Hayes Consultancy**

François Iris, Founder and Chief Scientific Officer, **Bio-Modeling Systems**

Peter Jenner, Chief Scientific Officer, **Proximagen**

Anders Haegerstrand, Chief Scientific Officer, **NeuroNova**

John Sinden, Chief Scientific Officer, **ReNeuron**

Ian Pike, Chief Business Officer, **Proteome Sciences**

Kevin Craig, Chief Medical Officer, **P1vital**

Aaron Chuang, Scientific Manager, Stem Cell Research, **GlaxoSmithKline**

Leslie Iversen, Visiting Professor, Department of Pharmacology, **University of Oxford**

John Hardy, Professor of Neuroscience, **University College London**

Stephen Minger, Senior Lecturer in Stem Cell Biology, **King's College London**

Jose de Leon, Professor of Psychiatry, College of Medicine, **University of Kentucky**

Steve England, Associate Research Fellow, **Pfizer**

Will Spooren, R&D Leader, CReD, **F. Hoffmann-La Roche**

Fabrizio Gasparini, Senior Research Investigator, **Novartis**

Associate
Sponsor



Media Partners



Organised By

To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com

visiongain

Conference Introduction

CNS Drug Development

15th - 16th December 2008, London, UK

The global CNS pharmaceuticals market, worth £55bn a year with 8% growth in 2007, is poised to become the number one target for drug development during the next decade¹.

Dear Colleague,

In the middle of the global credit crunch, the central nervous system drug market is booming. Population growth, better diagnosis and unmet clinical needs mean 70 companies are competing for a market spanning from pain to schizophrenia to obesity.

And, as we all live longer, the number of people with neurodegenerative diseases is spiraling. In Europe and the US alone, this will mean 13.2 million Alzheimer's and 16.2 million Parkinson's disease sufferers by 2050; a 300% increase on numbers today².

If effective therapies are not found soon, the financial, societal and emotional costs of these disorders will be staggering. At the same time, many basic needs in CNS R&D remain unmet, such as reducing production schedule and compound attrition rates. How can such inter-related challenges be overcome?

By attending this conference you will understand how these and other issues are being resolved, including:

- How can drug delivery across the blood-brain barrier be improved?
- Have new biomarkers been identified to track disease existence or progression?
- Will human-animal hybrid embryo research bring new therapies for neurodegenerative diseases? And what role will stem cell and other regenerative therapies play?
- How can new medicines that improve cognition be validated in clinical trials?
- Should 'smart drugs' be available to the general public?
- Is there a future for pharmacogenomics in psychiatry?
- How can we overcome patient heterogeneity?

To answer these questions, Visiongain has assembled an august selection of senior representatives from top ten big pharma companies, industry and academia. These include 'expert's experts' in translational research, molecular neuroscience, and regenerative medicine.

I look forward to meeting you at the conference.

Yours sincerely,



John Shah
Conference Producer

Who will be there?

Senior VPs, Heads, Directors, CSOs and Project leaders in:

- CNS Clinical Discovery/Nervous System Research
- Neuroscience
- Neurology
- Psychiatry/Molecular Psychiatry
- Drug Discovery/Drug R&D/Drug Design
- Emerging Targets/Lead Optimisation
- Stem Cell Research
- Therapeutics and Molecular Profiling
- Pain Management
- Protein Technologies
- Pre-Clinical/Clinical R&D
- Genomics/Proteomics/Bioinformatics/Neuroinformatics
- Translational Medicine
- Global Marketing and Medicine
- Disease Genetics
- Pharmacology
- Imaging
- Immunology/Immunotherapy

Associate Sponsors:



Cambridge Cognition Ltd specialises in computerised cognitive testing. The company supplies products and services based on CANTAB®, the Cambridge Neuropsychological Test Automated Battery. The CANTAB tests are used for neuropsychological assessment in pharmaceutical clinical trials, academic research and healthcare around the world. The computerised neuropsychological tests in CANTAB®, used in academic research over more than 20 years, have been extensively validated, with a bibliography of (currently) over 500 peer-reviewed journal papers.

For further information please visit: www.cantab.com



Sovicell is dedicated to providing trusted state-of-the-art ADMET products and services that enable its customers to rapidly obtain accurate and reproducible pharmacokinetic data about their drug candidates. The TRANSIL technology platform underpins the Company's reliable membrane permeability and protein binding assays. While SOVICYTE cell lines form the core of Sovicell's drug metabolism and cytotoxicity assays.

For further information please visit: www.sovicell.com

Media Partners:



PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US.

For further information please email: corporate@pharmiweb.com



BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world's biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities.

For further information please visit: www.biotechnology-europe.com



Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide.

For further information please visit: www.futurepharmaus.com



InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus.

For further information please visit: www.In-Pharm.com

About visiongain:

Visiongain is a specialist business information company focused on providing cutting edge products and services across the Pharmaceutical/Biotech, Telecommunications, Defence and Finance sectors, which include reports, conferences, online daily news and offline news analysis and bespoke consultancy. With a commitment to innovation and excellence, visiongain offers flexible solutions to meet our clients' business intelligence needs, providing the right information at the right time to facilitate the commercial decision-making process. Our pharmaceutical products include Pharma Business Daily, the leading daily email newsletter for the pharmaceutical, biotech and healthcare industries, and a range of independent, high-quality, in-depth reports covering focused and topical areas of concern. Our pharmaceutical conferences address the hottest commercial, regulatory and technical topics and provide an ideal forum for debate and networking for pharmaceutical professionals from around the world.

For further information, please visit: www.visiongain.com

Sponsorship and exhibition opportunities:

This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a service or product to promote, you can do so at this event by:

- Hosting a networking drinks reception
- Taking an exhibition space at the conference
- Advertising in the delegate documentation pack
- Providing branded bags, pens, gifts, etc.

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's CNS Drug Development conference, please contact us:

Patricia Gallegos, +44 (0)20 7549 9952
patricia.gallegos@visiongaininglobal.com

¹NeuroInsights, (2008). *The Neurotechnology Industry 2008 Report*.

²Forman, M. et al., (2004). Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. *Nature Medicine*, **10** (10), pp. 1055-1063.

09:30 Registration and refreshments

10:00 Opening address from the chair

Simon Lovestone

Director NIHR Biomedical Research Centre for Mental Health,
Institute of Psychiatry, **King's College London**

10:10 CNS drug discovery- where are we and what are the prospects for the future?

- Medical needs and commercial opportunities in CNS diseases
- Success rates for CNS drug discovery and development
- Difficulties and potential solutions – exemplified by programmes from several CNS diseases
- Some exciting new areas in CNS drug discovery

Ann Hayes

Owner, **The Ann Hayes Consultancy**
Formerly Director of Drug Discovery, **GlaxoWellcome**

10:50 Overcoming the blood-brain barrier in CNS pharmacotherapy

- Physicochemical barriers to brain penetration- new insights from *in silico*, *in vitro* and *in vivo* models
- Biological barriers to brain penetration: P-glycoprotein and other transport modulators
- Establishing the link between blood concentration, receptor occupation and behaviour in preclinical & clinical trials

Simone Braggio

Director, Neurosciences CEDD DMPK
GlaxoSmithKline

11:30 Morning refreshments

11:45 TRANSIL Brain Absorption: A novel *in vitro* model for predicting CNS penetration

- Prediction of brain availability (logBB and fu brain)
- Prediction of concentration at receptor site in brain
- Classification of CNS+/CNS- compounds
- Fast: 2 min incubation time
- Easy: First ready-to-use assay kit

Hinnerk Boriss

Chief Executive Officer
Sovicell

12:05 Biomarkers in CNS diseases: can serendipity lead to relevance?

- What relevance do biomarkers identified by statistical occurrence have for heterogenous CNS diseases?
- Overcoming methodological problems to obtain physiologically relevant biomarkers
- Novel and unique approaches to developing CNS experimental medicine models to accelerate drug discovery.

Chair:

François Iris

Founder and Chief Scientific Officer
Bio-Modeling Systems

Kevin Craig

Medical Director
P1vital

John Hardy

Professor of Neuroscience
University College London

Rémy Luthringer

Chief Executive Officer
Forenap Pharma

12:45 Translational medicine and explorative clinical trials in neurology

- The challenges of transitioning preclinical CNS projects to human trials
- The usefulness of *in vitro* and animal data, to build a comprehensive PK/PD package and identify disease indication
- The challenges to reach early proof of mechanism and proof of concept understanding for CNS therapeutics

Johan Luthman

Global Head Exploratory Medicine, PoC Management & Liaison
Merck Serono

13:25 Networking lunch

Focus on stem cell and regenerative therapies in CNS drug discovery

14:30 Research potential of pluripotent stem cells for CNS discovery

- Current strategies for the generation of pluripotent stem cells
- Modelling of human CNS disorders using pluripotent stem cells
- Use of human pluripotent stem cells for target discovery in CNS research

Stephen Minger

Senior Lecturer in Stem Cell Biology
Stem Cell Biology Laboratory, King's College London

15:10 Translating neural stem cells into clinical products: where are we now?

- Addressing product issues: designing a manufacturing, testing and release strategy
- Addressing preclinical issues: can we ever prove implanted stem cells are not a safety concern?
- Addressing clinical concerns: has Europe got it right with the ATMP regulations?

John Sinden

Chief Scientific Officer
ReNeuron

15:50 Afternoon refreshments

16:10 Exploring neurogenesis mechanisms for novel CNS therapeutics

- Opportunities for neurogenesis therapy in CNS diseases.
- Regulation of proliferation & differentiation of neural stem cells.
- Autocrine versus paracrine regulation of neural stem cells.

Aaron Chuang

Scientific Manager, Stem Cell Research
GlaxoSmithKline

16:50 Neurogenesis and neuroprotection in Parkinson's disease and amyotrophic lateral sclerosis

- The impact of altered stem/progenitor cell activity in neurodegenerative disease
- sNN0031/PDGFBB - towards the clinic to promote neurogenesis and dopamine system restoration
- sNN0029/VEGF165 - towards the clinic to protect motor neurons
- Direct application of protein drugs to the CNS- pros and cons

Anders Haegerstrand

Chief Scientific Officer
NeuroNova

17:30 Closing remarks from the chair

17:40 Networking drinks

Take your discussions further and build new relationships in a relaxed and informal setting.

09:30 Registration and refreshments

10:00 Opening address from the chair

Simon Lovestone
Director NIHR Biomedical Research Centre for Mental Health,
Institute of Psychiatry, **King's College London**

10:10 New insights in neuropathic pain relief

- Key insights from sodium channel blockers
- Identifying new drug targets
- Molecular epidemiology of pain: a new discipline for drug discovery

Steve England
Associate Research Fellow
Pfizer

10:50 Using biomarkers to support drug development in Alzheimer's disease

Ian Pike
Chief Business Officer
Proteome Sciences

11:10 Panel discussion: new targets in Alzheimer's disease

- Non-tau approaches: un embarras de richesse?
- The tangle pathology of AD as a pharmaceutical target

Jackie Hunter
Senior Vice President, Science Environment Development
GlaxoSmithKline

Claude Wischik
Executive Chairman
TauRx Therapeutics

11:50 Morning refreshments

12:05 Understanding the future treatment of Parkinson's disease – a preclinical perspective

- New symptomatic treatments
- Non-dopaminergic therapies
- Neuroprotection
- Neurorestoration

Peter Jenner
Chief Scientific Officer
Proximagen

12:45 Harnessing pre-clinical behavioural neuroscience for drug discovery and bridging the gap to clinical research

- What are the current obstacles to neuroscience drug discovery?
- Overcoming problems of preclinical model validation
- Go-it-alone or go-by-consortia: making the whole more than the sum of the parts

Mark Tricklebank
Director, Psychiatric Disorders Drug Hunting Team
Lilly UK

13:25 Networking lunch

14:25 Cognitive testing in clinical trials

- Latest methodological advances in assessing cognitive function
- Identifying cognition enhancement: the state of the art
- Determining the magnitude, profile and everyday relevance of changes to cognitive ability

Keith Wesnes
Chief Executive
Cognitive Drug Research

15:05 Panel discussion: recent discoveries in affective CNS disorders

- mGluR5 allosteric antagonists: identification, characterization and potential for therapeutic applications
- Anxiolytics: new results from animal and clinical trials
- NK3 receptor antagonists – a novel class of anti-psychotics?

Fabrizio Gasparini
Senior Research Investigator
Novartis

Will Spooen
R&D Leader, CR&D
F. Hoffmann-La Roche

15:55 Afternoon refreshments

16:10 Pharmacogenomics: the promise of personalised medicine for CNS disorders

- First generation pharmacogenetic tests in psychiatry
- Current challenges in applying pharmacogenomic tests in clinical practice
- Future research directions

Jose de Leon
Professor of Psychiatry, College of Medicine
University of Kentucky

16:50 The future of cognition-enhancing drugs

- Drugs and attention-deficit disorders
- Preparing for drugs that improve memory, concentration and learning
- Can 'smart drugs' ameliorate cognitive decline and boost memory and creativity?
- Treating or enhancing? Ethical implications

Leslie Iversen
Visiting Professor, Department of Pharmacology, **University of Oxford**
Formerly Director of the Neuroscience Research Centre
Merck Research Laboratories

17:30 Chair's closing remarks

17:40 End of conference

Registration Form

CNS Drug Development

15th - 16th December 2008, London, UK

For multiple bookings

Photocopy this form or visit www.visiongain.com

Conf. code **B2B**

Standard Prices

Conference only Fee: £1299 VAT: £194.85 Total: £1493.85
Academics and Not for Profit Fee: £499 VAT: £74.85 Total: £573.85

Promotional Literature Distribution

Distribution of your company's promotional literature to all conference attendees

Fee: £999 VAT: £149.85 Total: £1148.85

Details

Forename: Surname:

Job Title: Company:

Main Switchboard Number:

Address:

Country: Postcode:

Phone: Fax:

Email:

Signature:

I confirm that I have read and agree to the terms and conditions of booking

Methods of payment

Payment must be made in sterling

By Mail: Complete and return your signed registration form together with your cheque payable to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK

By Fax: Complete and fax your signed registration form with your credit card details to +44 (0) 20 7549 9932

By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details

By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932

By Bank Transfer:

Visiongain Ltd A/C: visiongain Ltd
Barclays Bank Sort Code: 20-71-64
Mayfair Group Account No: 6038 7118
27 Regent Street Swift Code: BARC GB22
London SW1Y 4UB, UK IBAN: GB80 BARC 20716460387118

Please debit my credit card:

Access MasterCard Visa American Express

Card number:

Expiry Date:

Security number (last 3 digits on back of credit card):

Signature:

Cardholder's name:

News updates


Please tick if you do not want to receive email news updates in the future

CNS Drug Development

15th - 16th December 2008

Location: BSG Conference Centre

Address:
226 - 236 City Road
London
EC1V 2TT
United Kingdom



How to book

Email: conferences@visiongainglobal.com

Web: <http://www.visiongain.com>

UK Office:

Tel: +44(0) 20 7336 6100

Fax: +44(0) 20 7549 9932

Visiongain Ltd
BSG House
226-236 City Road
London
EC1V 2QY
UK

General information

Venue: Directions: BSG Conference Centre 226 - 236 City Road, London, EC1V 2TT, United Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340

Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices.

Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences and executive briefings. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or organisation and are not transferable between countries.

Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.

Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses.

Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1988. Your personal information contained in this form may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect.

Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).

VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT.

How we will contact you: Visiongain Ltd's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.

Unable to attend

Obviously nothing compares to being there but you need not miss out. Simply tick the box and send with your payment. You will receive your copy of the event CD Rom two weeks after the event.

Yes, please send me a copy of the CD for **Price£550** **VAT:£96.25** **Total:£646.25**

Office use only

A B C D E F G H I J K L M